Publication:
Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Simple item page
dc.contributor.authorDANE, FAYSAL
dc.contributor.authorsYASİN A. İ., Aydin S. G., SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli C., Ozturk A., Perkin P., Demirtas D., Erdemoglu E., et al.
dc.date.accessioned2023-02-14T06:28:18Z
dc.date.available2023-02-14T06:28:18Z
dc.date.issued2022-03-01
dc.description.abstractAim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov)
dc.identifier.citationYASİN A. İ., Aydin S. G., SÜMBÜL B., KORAL L., ŞİMŞEK M., Geredeli C., Ozturk A., Perkin P., Demirtas D., Erdemoglu E., et al., "Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study", FUTURE ONCOLOGY, cilt.18, ss.1235-1244, 2022
dc.identifier.doi10.2217/fon-2021-1248
dc.identifier.endpage1244
dc.identifier.issn1479-6694
dc.identifier.startpage1235
dc.identifier.urihttps://hdl.handle.net/11424/286170
dc.identifier.volume18
dc.language.isoeng
dc.relation.ispartofFUTURE ONCOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectONCOLOGY
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectcancer
dc.subjectchemotherapy
dc.subjectCoronaVac
dc.subjectCOVID-19
dc.subjectCOVID-19 vaccines
dc.subjectimmunotherapy
dc.subjectmalignancy
dc.subjectSARS-CoV-2
dc.titleEfficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
dc.typearticle
dspace.entity.typePublication
local.avesis.idbbba4845-6058-436d-bb14-f062eeebfebd
local.indexed.atWOS
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication059ce50a-8d16-4fc6-a86c-85c9baa19a5c
relation.isAuthorOfPublication.latestForDiscovery059ce50a-8d16-4fc6-a86c-85c9baa19a5c

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs